H0RSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced results from a Phase I head-to-head clinical trial comparing LCP-Tacro, the Company’s lead product candidate being developed as a once-daily tablet version of tacrolimus, to Advagraf, currently marketed in a few European countries as a once-daily capsule version of tacrolimus. The results confirm that with LCP-Tacro, the Company is developing an improved version of tacrolimus when compared to both Advagraf and Prograf®, the latter being the world’s leading drug for immunosuppression following organ transplantation. The Phase I head-to-head clinical trial, designed as a multi-dose trial, enrolled 19 healthy volunteers. Clinical data confirmed that LCP-Tacro, when compared to Advagraf, demonstrated:
